MedTrace Logo

Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis

NCT04576000 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2022-01-04

No results posted yet for this study

Summary

This study aims to provide new mechanistic insights into the molecular determinants of response or nonresponse to Janus Kinase inhibitor therapy and the biological heterogeneity that exists in Ulcerative Colitis. This study will include patients who are initiating Janus Kinase inhibitor therapy according to standard of care. This study consists of:

* Part 1: 8 or 10 week induction therapy followed by an 8-week maintenance therapy
* Part 2: Patients who continue Janus Kinas inhibitor therapy after part 1 will be followed further for a total of 2 years, or until discontinuation of Janus Kinase inhibitor therapy (whichever is first)

Conditions

Interventions

DRUG

Janus Kinase Inhibitor

Janus Kinase inhibitor induction therapy will be administered according to Standard Of Care (SOC)

Sponsors & Collaborators

  • Alimentiv Translational Research Consortium

    collaborator UNKNOWN

  • Alimentiv Inc.

    lead OTHER

Principal Investigators

  • Vipul Jairath, MD, PhD · Alimentiv Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-25
Primary Completion
2020-12-15
Completion
2021-12-02
FDA Drug
Yes

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04576000 on ClinicalTrials.gov